2016-03-10T00:00:00.000-05:00
non-covalent oral inhibitor,0.466473
Debbie Thomas,0.315914
upfront BTK usage,0.720264
Ia clinical trial,0.747287
greatest clinical benefits,0.300768
frontline AML treatment,0.502008
thanks,0.741111
Takeda-partnered pan-RAF inhibitor,0.396999
vosaroxin,0.153376
Yes. Thanks,0.856813
kinase inhibitor program,0.264124
question,0.632044
end,0.217123
great question,0.782736
BTK inhibitor,0.286219
PDK-1 inhibitor program,0.317336
Mr. Dan Swisher,-0.291844
Yes. Michelle thanks,0.80034
European AML market,0.864483
kinase inhibitor programs,0.266536
kinase selectivity,0.700422
questions,0.275548
AML patients,0.60367
vosaroxin development program,-0.328343
Operator Instructions,0.27751
Yes.,0.637287
new treatment options,0.60367
human clinical data,-0.480775
kinase selectivity profile,0.712652
kinase selectivity panel,0.688191
Jim Birchenough,0.325764
BTK inhibitors,0.705435
forward-looking statements,0.530211
Dan Swisher,-0.291844
actual clinical data,0.608437
